Bio-Techne Corp (TECH): Price and Financial Metrics


Bio-Techne Corp (TECH): $511.45

-27.43 (-5.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TECH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

TECH POWR Grades


  • Growth is the dimension where TECH ranks best; there it ranks ahead of 92.42% of US stocks.
  • TECH's strongest trending metric is Growth; it's been moving up over the last 48 weeks.
  • TECH ranks lowest in Value; there it ranks in the 37th percentile.

TECH Stock Summary

  • TECH's current price/earnings ratio is 149.43, which is higher than 95.53% of US stocks with positive earnings.
  • The price/operating cash flow metric for BIO-TECHNE Corp is higher than 92.5% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 22.54, BIO-TECHNE Corp has a higher such ratio than 91.03% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to BIO-TECHNE Corp, a group of peers worth examining would be RGEN, HZNP, SPSC, VSAT, and OMCL.
  • Visit TECH's SEC page to see the company's official filings. To visit the company's web site, go to www.bio-techne.com.

TECH Valuation Summary

  • In comparison to the median Healthcare stock, TECH's price/earnings ratio is 280.55% higher, now standing at 138.9.
  • TECH's price/sales ratio has moved up 9.9 over the prior 243 months.
  • TECH's price/sales ratio has moved up 9.9 over the prior 243 months.

Below are key valuation metrics over time for TECH.

Stock Date P/S P/B P/E EV/EBIT
TECH 2021-08-31 21.0 12.5 138.9 121.1
TECH 2021-08-30 21.2 12.6 140.8 122.7
TECH 2021-08-27 20.8 12.4 137.8 120.1
TECH 2021-08-26 20.7 12.3 137.3 119.6
TECH 2021-08-25 21.0 12.5 139.2 121.3
TECH 2021-08-24 22.3 12.3 102.8 85.7

TECH Growth Metrics

  • Its 4 year revenue growth rate is now at 56.56%.
  • The 5 year price growth rate now stands at 214.82%.
  • The 2 year revenue growth rate now stands at 21.83%.
Over the past 33 months, TECH's revenue has gone up $269,682,000.

The table below shows TECH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 931.032 352.164 140.41
2021-03-31 847.838 274.935 184.296
2020-12-31 798.966 249.538 174.946
2020-09-30 759.647 230.687 248.294
2020-06-30 738.691 205.217 229.296
2020-03-31 754.522 216.372 186.912

TECH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TECH has a Quality Grade of B, ranking ahead of 81.37% of graded US stocks.
  • TECH's asset turnover comes in at 0.44 -- ranking 103rd of 677 Pharmaceutical Products stocks.
  • BIIB, URGN, and TMBR are the stocks whose asset turnover ratios are most correlated with TECH.

The table below shows TECH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.440 0.680 0.188
2021-03-31 0.412 0.673 0.250
2020-12-31 0.392 0.666 0.240
2020-09-30 0.376 0.662 0.330
2020-06-30 0.372 0.654 0.302
2020-03-31 0.387 0.660 0.271

TECH Price Target

For more insight on analysts targets of TECH, see our TECH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $549.60 Average Broker Recommendation 1.36 (Strong Buy)

TECH Stock Price Chart Interactive Chart >

Price chart for TECH

TECH Price/Volume Stats

Current price $511.45 52-week high $543.85
Prev. close $538.88 52-week low $242.03
Day low $508.72 Volume 213,000
Day high $535.43 Avg. volume 268,723
50-day MA $493.69 Dividend yield 0.24%
200-day MA $415.91 Market Cap 19.99B

Bio-Techne Corp (TECH) Company Bio


Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. The company was founded in 1976 and is based in Minneapolis, Minnesota.


TECH Latest News Stream


Event/Time News Detail
Loading, please wait...

TECH Latest Social Stream


Loading social stream, please wait...

View Full TECH Social Stream

Latest TECH News From Around the Web

Below are the latest news stories about BIO-TECHNE Corp that investors may wish to consider to help them evaluate TECH as an investment opportunity.

Top Healthcare Stocks for October 2021

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2021.

Yahoo | September 22, 2021

Bio-Techne Corporation's (NASDAQ:TECH) Stock Is Going Strong: Have Financials A Role To Play?

Most readers would already be aware that Bio-Techne's (NASDAQ:TECH) stock increased significantly by 21% over the past...

Yahoo | September 20, 2021

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACH...

Benzinga | September 16, 2021

CEO PayWatch: Kummeth of Bio-Techne earns $40.5M as firm''s diagnostic tools aided in pandemic fight

No summary available.

Star Tribune | September 15, 2021

Bio-Techne Launches ExCellerate™ iPSC Expansion Medium

Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows. The ExCellerate™ iPSC Expansion Medium is the latest addition to Bio-Techne's comprehensive portfolio of products and services for Regenerative Medicine. It is designed to fit seamlessly into their offerings for stem cell workflows, including cell isolation, reprogramming, genome eng

Yahoo | September 14, 2021

Read More 'TECH' Stories Here

TECH Price Returns

1-mo 3.32%
3-mo 13.67%
6-mo 31.84%
1-year 110.54%
3-year 154.54%
5-year 389.87%
YTD 61.43%
2020 45.40%
2019 52.67%
2018 12.60%
2017 27.40%
2016 15.77%

TECH Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TECH Dividend History

Continue Researching TECH

Want to see what other sources are saying about BIO-TECHNE Corp's financials and stock price? Try the links below:

BIO-TECHNE Corp (TECH) Stock Price | Nasdaq
BIO-TECHNE Corp (TECH) Stock Quote, History and News - Yahoo Finance
BIO-TECHNE Corp (TECH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0045 seconds.